Evotec AG (Germany), a drug discovery alliance and development partnership company, announced that it has entered into a research collaboration with Immuneering Corporation (USA), a leader in data-driven drug discovery, to discover novel small molecules for rare hereditary metabolic diseases.
The research collaboration brings together Evotec’s induced pluripotent stem cell platform and broad drug discovery capabilities with Immuneering’s unique Artificial Intelligence-driven drug discovery platform to accelerate ligand identification for novel targets. As part of the collaboration, Evotec will use Immuneering’s proprietary computational drug discovery platform to analyse public and proprietary data to advance identification of novel drug candidates that can ultimately lead to new medicines for rare hereditary metabolic diseases.
The Immuneering team applies proprietary computational biology methods and an advanced drug discovery platform to high-throughput molecular data, re-engineering the process by which new medicines are discovered and developed to be faster, less expensive, and more likely to succeed. The company’s drug discovery platform identifies “hits” (the molecular structures that form the basis of new medicines) in a matter of days or weeks, rather than the months or years of target identification and high-throughput screening typically required. Immuneering also provides bioinformatics and computational biology services for pharmaceutical companies to generate biological insights that enhance the clinical and commercial success of medicines (genetic, genomic, and proteomic data analysis).